Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by AMG National Trust Bank

AMG National Trust Bank increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 29.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,359 shares of the medical equipment provider’s stock after purchasing an additional 11,339 shares during the quarter. AMG National Trust Bank’s holdings in Zimmer Biomet were worth $4,960,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Key Financial Inc lifted its stake in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its holdings in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its position in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC bought a new position in Zimmer Biomet during the 3rd quarter valued at $31,000. Finally, Mather Group LLC. acquired a new position in shares of Zimmer Biomet during the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.5%

NYSE:ZBH opened at $98.74 on Friday. The stock has a market cap of $19.57 billion, a PE ratio of 27.89, a price-to-earnings-growth ratio of 2.03 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock’s 50-day moving average is $90.64 and its two-hundred day moving average is $95.82.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period last year, the company posted $2.31 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 5th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price target for the company from $94.00 to $120.00 in a report on Monday, January 5th. Sanford C. Bernstein raised their price objective on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. Finally, Canaccord Genuity Group decreased their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.